Current treatments of relapsing-remitting multiple sclerosis (RRMS) with immunosuppressive or immunomodulatory drugs have been shown to modify the course of the disease in a significative number of patients. However, in many cases, the response to either interferon β (IFN-β) or azathioprine (AZA) treatments was not satisfactory and new therapeutic approaches are needed. We studied clinical and MRI efficacy, safety and tolerance of AZA and IFN-β1a combined therapy in 23 patients with clinically definite RRMS, who had not previously been responsive to either monotherapies. Our cases were divided into three subgroups: 8 previously untreated patients (subgroup A) with at least 2 years of natural course of the disease, 8 patients (subgroup B) previously treated with AZA for 2 years and 7 patients (subgroup C) previously treated with IFN-β1a for 2 years. The baseline Expanded Disability Status Scale (EDSS) ranged from 2 to 4 in all subgroups. All patients completed 2 years of combined treatment with a dose of AZA adjusted to reduce lymphocyte count down to 1,000 ± 100/µl in association with IFN-β1a at a dose of 6 MIU every other day. The mean number of relapses during the combined treatment period was significantly lower than that observed before combined therapy in all the three subgroups. Also, the mean ΔEDSS score was significantly lower during combined treatment than in monotherapy in subgroups B and C. Moreover, after 2 years of combined treatment, the number of new T1 hypointense lesions, the number and volume of proton density/T2 hyperintense lesions and the gadolinium enhancement of T1 hypointense lesions were significantly lower than before combined treatment. After 2 years of treatment, this combination therapy appears to be safe and well tolerated and no serious side effects were reported. Despite some limitations of our study design, the information regarding efficacy, safety and tolerance of the association of AZA and IFN-β is most encouraging.

Keywords:
Multiple sclerosis, Combined therapy, Azathioprine, Interferon β1a
1.
Yudkin PL, Ellison GW, Ghezzi A, Goodkin DE, Hughes RA, McPherson K, Mertin J, Milanese C: Overview of azathioprine treatment in multiple sclerosis. Lancet 1991;338:1051–1055.
2.
The IFNβ Multiple Sclerosis Study Group: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Clinical results of a multicenter, randomised, double-blind, placebo-controlled trial. Neurology 1993;43:655–661.
3.
Jacobs LD, Cookfair DL, Rudick RA, Hemdon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE 3rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH, et al: Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285–294.
4.
Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis Study Group: Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis. Lancet 1998;352:1498–504.
5.
Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H: Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707–717.
6.
Kappos L: Combinations of drugs. Mult Scler 1996;1:400–403.
7.
Canadian Cooperative Multiple Sclerosis Study Group: The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991;337:441–446.
8.
Sorensen PS, Wansher B, Szpirt W, Jensen CV, Ravnborg M, Christiansen P, Schreiber K, Nordenbo A: Plasma exchange combined with azathioprine in multiple sclerosis using serial gadolinium-enhanced MRI to monitor disease activity: A randomised single-masked cross-over pilot study. Neurology 1996;46:1620–1625.
9.
Patti F, Castaldi ML, Nicoletti F, Reggio E, Nicoletti A, Reggio A: Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis. J Neurol Neurosurg Psychiatry 2001;71:404–407.
10.
Calabresi PA, Wilterdink JL, Rogg JM, Mills P, Webb A, Whartenby KA: An open-label trial of combination therapy with interferon β-1a and oral methotrexate in MS. Neurology 2002;58:314–317.
11.
Moreau T, Blanc S, Riche G, Confavreux C: Sclérose en plaques: l’étude Erazimus. Neurologies 1998;5:40.
12.
Markovic–Plese S, Bielekova B, Kadom N, Leist TP, Martin R, Frank JA, McFarland HF: Longitudinal MRI study: The effects of azathioprine in MS patients refractory to interferon β-1b. Neurology 2003;60:1849–1851
13.
Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW: New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983;13:227–231.
14.
Kurtzke JF: Rating neurological impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983;33:1444–1452.
15.
Palace J, Rothwell P: New treatments and azathioprine in multiple sclerosis Lancet 1997;350:261.
16.
Lublin F, Cutter G, Elfont R, et al: A trial to assess the safety of combining therapy with interferon beta-1a and glatiramer acetate in patients with relapsing MS (abstract). Neurology 2001;56(suppl 3):A148.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.